Connect with us

Hi, what are you looking for?

Monday, Dec 4, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Antidepressants enhance DMT efficacy in patients with severe depression: Small Pharma study

The study found that 100 per cent of patients were responsive and 92 per cent went into remission

Antidepressants enhance DMT efficacy in patients with severe depression: Small Pharma study
DMT in powder form. Photo by DMTrott via Wikimedia Commons.

Popular antidepressants may enhance the efficacy of the classical psychedelic DMT when given to patients suffering from major depressive disorder, according to a new study by the British biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF).

On Wednesday, the company announced the results from its Phase Ib study investigating the interaction between selective serotonin reuptake inhibitors (SSRIs) and SPL026, a native N, N-dimethyltryptamine (DMT). The study revealed that by the fourth week, all patients taking SSRIs responded to DMT with 92 per cent in remission from depression.

Previous studies required patients to discontinue their SSRI treatment before receiving SPL026, which often resulted in a disruptive experience for patients. This new study aimed to address this limitation and assess the safety and efficacy of co-administering SPL026 alongside SSRIs, which are the current standard of care for MDD.

Antidepressants enhance DMT efficacy in patients with major depressionSmall Pharma study

Table via Small Pharma.

Read more: Cybin inks agreement to acquire DMT drug developer Small Pharma

Read more: Small Pharma gets approval for upcoming injectable DMT trial on humans

The study involved 171 patients with moderate to severe MDD, divided into two cohorts, one with SSRIs and the other without SSRIs.

Results revealed that SPL026 was well-tolerated by all patients, with no serious drug-related adverse events reported. A small number of mild to moderate drug-related adverse events were observed, and most resolved during the dosing visit. These findings indicate the safety and tolerability of combining SPL026 with SSRIs.

The most significant and exciting outcome of the study was observed in terms of efficacy. While SPL026 demonstrated antidepressant effects in both cohorts, the SSRI Cohort exhibited a notably greater magnitude of improvement compared to the non-SSRI cohort.

The study suggests the combination potentially provides a more effective treatment option for MDD patients who have previously struggled to find relief.

Small Pharma’s approach may eliminate the need for patients to withdraw from SSRIs, thus streamlining the clinical development pathway and potentially providing earlier access to this treatment.

While these results are promising, further research and clinical trials will be necessary to validate and expand upon these findings.

Small Pharma stock fell by 5.88 per cent on Wednesday to $0.16 on the Canadian Ventures Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


This is the first shipment that will be used specifically under the country's Authorized Prescriber Scheme enacted in July


Dana Larsen owns three shops in Vancouver that openly sell psychedelics like psilocybin mushrooms, DMT and peyote


The license was granted to Rua Bioscience, a medical cannabis company based in Tairāwhiti Gisborne


All participants in the placebo group reported a 50 per cent drop in depression symptoms after surgery